Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2008 2
2009 1
2010 5
2011 1
2012 2
2013 2
2014 4
2015 4
2016 4
2017 7
2018 13
2019 15
2020 15
2021 7
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Castillo JJ, et al. Among authors: lansigan f. Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. Br J Haematol. 2019. PMID: 29527667 Free article. Clinical Trial. No abstract available.
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS, Bengston E, Redd R, Barnes JA, Takvorian T, Sokol L, Lansigan F, Armand P, Shah B, Jacobsen E, Martignetti R, Turba E, Metzler S, Patterson V, LaCasce AS, Bello CM. Abramson JS, et al. Among authors: lansigan f. Blood Adv. 2023 Apr 11;7(7):1130-1136. doi: 10.1182/bloodadvances.2022008420. Blood Adv. 2023. PMID: 36053786 Free PMC article. Clinical Trial.
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske T, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Gerson JN, et al. Among authors: lansigan f. Blood Adv. 2023 Dec 26;7(24):7393-7401. doi: 10.1182/bloodadvances.2023010757. Blood Adv. 2023. PMID: 37874912 Free PMC article.
Cutaneous T-cell lymphoma.
Lansigan F, Choi J, Foss FM. Lansigan F, et al. Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x. doi: 10.1016/j.hoc.2008.07.014. Hematol Oncol Clin North Am. 2008. PMID: 18954747 Review.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Orellana-Noia VM, et al. Among authors: lansigan f. Blood. 2022 Jan 20;139(3):413-423. doi: 10.1182/blood.2021012888. Blood. 2022. PMID: 34570876 Free PMC article.
Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M. Samples L, et al. Among authors: lansigan f. Blood Adv. 2024 Feb 2;8(9):2085-93. doi: 10.1182/bloodadvances.2023011569. Online ahead of print. Blood Adv. 2024. PMID: 38315043 Free PMC article.
84 results